logo
Areas in city of Frederick are most socially vulnerable in county, Census data shows

Areas in city of Frederick are most socially vulnerable in county, Census data shows

Yahoo01-06-2025
Areas in and near the city of Frederick — particularly around Francis Scott Key Mall and Westview Business Park and next to Fort Detrick's Area B — are considered the most socially vulnerable in Frederick County.
Social vulnerability is the demographic and socioeconomic factors of an area that harm communities that experience hazards or disasters, according to the U.S. Agency for Toxic Substances and Disease Registry (ATSDR).
Disasters can be natural or caused by humans, like extreme weather events or chemical spills, and disease outbreaks, like the COVID-19 pandemic.
Demographic and socioeconomic factors that impact how socially vulnerable a community is include poverty, lack of access to transportation and crowded housing.
ATSDR and the Centers for Disease Control and Prevention have created the Social Vulnerability Index to measure U.S. Census tracts across the country.
SVI scores can range from 0 to 1, with 1 being the most socially vulnerable.
SVI scores can help communities figure out where resources should be focused for people in need.
The index uses 16 Census variables to identify communities that may need support before, during and after disasters. The variables are grouped into four categories, then combined into an overall social vulnerability score.
The categories are socioeconomic status; household characteristics; racial and ethnic minority status; and housing type and transportation.
In addition to having an overall SVI score, communities have scores for each category.
The most recent SVI scores available on the SVI Interactive Map are from 2022.
Social vulnerability in Frederick County in 2022 by U.S. Census tracts
The entirety of Frederick County had a low SVI score of 0.1234 when compared nationwide, but certain tracts within the county have high scores compared to tracts across the U.S.
The most socially vulnerable area in Frederick County in 2022 was a Census tract on the southeastern edge and just outside the city of Frederick, with a score of 0.8687.
The tract includes a large portion of the Ballenger Creek community and encompasses I-270 from where the highway intersects with I-70 to where it crosses the Monocacy River. It also includes the entirety of Crestwood Boulevard.
Locations in this tract include Francis Scott Key Mall, Westview Business Park and Industrial Center East, as well as neighborhoods around them.
The second most socially vulnerable area in the county was a Census tract in central Frederick, running from Rosemont Avenue to Opossumtown Pike outside Fort Detrick's main campus. Its score is 0.8087.
The Villa Estates, Antietam Village and College Estates communities fall within this tract. Some locations in this parcel include Heather Ridge School, an alternative school for middle and high schoolers, and Frederick Shopping Center.
The third most socially vulnerable area was a smaller Census tract right next to the Golden Mile in west Frederick, with a score of 0.7543.
This tract spans from a part of West Patrick Street to Shookstown Road, next to a residential community being built directly across from Fort Detrick's Area B. It also includes the entire Stonegate community.
Area B is a 399-acre section of the base that is detached from the main campus, between Kemp Lane and Shookstown Road. The section was used as a test site for the Army's biological warfare program in the mid-20th century.
After the program was ended in 1969, scientists disposed of hazardous waste in unlined trenches and pits in Area B, resulting in groundwater contamination.
Army scientists have spent decades studying the contamination and the extent to which it has spread.
These three Census tracts also had high SVI scores in 2020.
Socioeconomic status vulnerability in Frederick County in 2022 by U.S. Census tracts
Household characteristics vulnerability in Frederick County in 2022 by U.S. Census tracts
Racial and ethnic minority status vulnerability in Frederick County in 2022 by U.S. Census tracts
Housing type and transportation vulnerability in Frederick County in 2022 by U.S. Census tracts
Unsurprising findings
Frederick County's social vulnerability was included in the 2025 Community Health Needs Assessment, a document released every three years that illustrates the county's current picture of health and population.
This assessment is part of the Local Health Improvement Process, a collaboration between the county health department, Frederick Health and the Coalition for a Healthier Frederick County.
After the assessment comes out, a Local Health Improvement Plan is created outlining how to address these priorities and the county's health status through policies, programs and other initiatives.
Rissah Watkins, director of the county health department's Office of Planning, Assessment and Communication, writes the assessment.
When interviewed on Wednesday, Watkins said Frederick County is a mix of populated urban areas and rural areas.
She said she generally expects to see areas with more people living there to 'light up more' on a social vulnerability map.
She pointed out that that many Census tracts in the county with medium-high or high SVI scores are clustered around the city of Frederick, which makes sense given that it's a highly populated area.
For example, when looking at specifically housing type and transportation vulnerability, the darkest areas are in Frederick and the southern part of the county, where people who commute to Washington, D.C., may want to live.
Watkins said it isn't surprising those areas have higher SVI scores in this category because there are fewer housing options given the number of people there.
In Frederick, dozens of community resources are concentrated in the area.
However, Watkins said, other parts of the county are also socially vulnerable, even though there's fewer people living there, so the resources have to be spread out.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Thirsty Trump's Desperate Cold-Call About Nobel Peace Prize
Thirsty Trump's Desperate Cold-Call About Nobel Peace Prize

Yahoo

time7 hours ago

  • Yahoo

Thirsty Trump's Desperate Cold-Call About Nobel Peace Prize

President Donald Trump has stooped to cold calling Norwegian diplomats in his long-suffering bid to be awarded the country's coveted Noble Peace Prize. Norway's Finance Minister Jens Stoltenberg, the former NATO secretary-general, confirmed to Politico that Trump called him to discuss tariffs and economic cooperation between the two countries. 'It is true that President Trump called me a few days before his conversation with Prime Minister (Jonas Gahr) Støre. Several of the president's staff members also participated in the conversation, including Treasury Secretary Bessent and Trade Representative Greer,' said Stoltenberg. However, Norwegian newspaper Dagens Næringsliv reported on Thursday that the topic of the Nobel Peace Prize was also raised in their discussions, and it was the second such time that the topic was raised during a call. Stoltenberg added, 'I will not go into further detail about the content of the conversation.' In recent months, Trump has frequently proclaimed that he believes that he deserves a Nobel Peace Prize much more than the previous four presidents who have received the award—especially more than former President Barack Obama. '(Obama) didn't even know why the hell he got it, right? He still doesn't,' Trump told a Las Vegas audience last year during a campaign stop, The Independent reported. 'He got elected, and they announced he's getting the Nobel Prize. I got elected in a much bigger, better, crazier election, but they gave him the Nobel Prize.' In his second term, Trump has publicly ramped up the pressure to get his hands on the award and he has enlisted the help of his MAGA proxies to prove he is Nobel-worthy. Israel President Benjamin Netanyahu wrote a letter to the Norwegian Nobel Committee praising Trump for his role in negotiating the 2020 Abraham Accords. Laying it on thick, Netanyahu claimed that Trump was 'forging peace, as we speak, in one country in the region after another.' Armenia and Azerbaijan have also publicly come out in support of Trump winning the prize after a successful Aug. 8 summit at the White House saw the two countries walk away with a joint peace agreement to end a 37-year conflict, the Atlantic Council reported. 'I think President Trump deserved to have the Nobel Peace Prize,' Armenian Prime Minister Nikol Pashinyan said at the White House, 'and we will defend that, we will promote for that.' Now all eyes are on Trump's highly-anticipated meeting with Russian President Vladimir Putin in Alaska as he looks to finally put an end to Putin's full-scale invasion of Ukraine once and for all, something he promised to do on 'day one' of his presidency. A former aide in Trump's first term told The Hill 'there's no question the pressure's on' for the administration to secure the prize. 'Trump sees this prize as the ultimate capstone to how history will remember him,' they added. Yet even if Trump doesn't broker peace between Russian and Ukraine, MAGA pundit Geraldo Rivera declared that Trump deserves it anyway. 'If you have a president of the United States trying so hard... for peace, even if he's not totally successful, just the effort is so, it's so overt, it's so public, it's so aggressive. You know, he deserves recognition at least for that,' Rivera told Newsmax host Rob Finnerty on Wednesday. 'If he does end this war, Geraldo, can they deny him the Nobel Peace Prize?' Finnerty asked. 'Hell no,' Rivera said. 'I think that this and/or Gaza would put him on the fast track, and anyone to deny that, I think, would really be putting their partisan politics in front of their logic.' The Nobel Peace Prize will be awarded at a ceremony on Dec. 10, 2025, in Stockholm, Sweden. The Daily Beast has contacted White House representatives for comment on Trump's campaign push for the Nobel Peace Prize.

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns
Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Yahoo

time7 hours ago

  • Yahoo

Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns

Key Points CRISPR Therapeutics' first approved therapy, Casgevy, was a breakthrough. One of Casgevy's biggest achievements may be demonstrating the viability of CRISPR Therapeutics' strategy. The biotech company could soar if it can follow up that win with more clinical and regulatory milestones. 10 stocks we like better than CRISPR Therapeutics › Over the past few years, the market hasn't been kind to somewhat speculative, unprofitable stocks. CRISPR Therapeutics (NASDAQ: CRSP), a mid-cap biotech, fits that description. The company's shares are down by 24% since mid-2022. The S&P 500 is up 50% over the same period. Despite this terrible performance, there are reasons to believe that CRISPR Therapeutics could still generate life-changing returns for investors willing to be patient. Here's how the biotech could pull it off. CRISPR Therapeutics' first success CRISPR Therapeutics' first approval was for Casgevy, a treatment for sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), which it developed in collaboration with Vertex Pharmaceuticals. Before Casgevy, no CRISPR-based gene-editing medicine had been approved. While it became the first, it still faces some challenges. Ex vivo gene-editing therapies require a complex manufacturing and administration process that can only be performed in authorized treatment centers (ATCs). Moreover, they're expensive. Casgevy costs $2.2 million in the U.S. Getting third-party payers on board for that is no easy feat. Still, CRISPR Therapeutics and Vertex Pharmaceuticals are making steady progress. As of the second quarter, CRISPR Therapeutics had achieved its goal of activating 75 ATCs. It had also secured reimbursement for eligible patients in 10 countries. The two companies estimate there are roughly 60,000 eligible SCD and TDT patients in the regions they have targeted. Let's say they continue to strike reimbursement deals and can count on third-party coverage for 70% of this target population (42,000 people), then go on to treat another 30% of that group in the next decade (12,600 patients). Assuming they could extend that $2.2 million price tag to those countries, Casgevy could generate more than $27.7 billion over this period. Based on its agreement with Vertex, 40% would go to CRISPR Therapeutics, or roughly $11.1 billion over a decade. That's not bad, but it's not that impressive either. So, while Casgevy could contribute meaningfully to CRISPR Therapeutics' results -- and may even reach blockbuster status at some point -- the medicine may primarily serve as a proof of concept to demonstrate that the biotech's approach can be effective. Substantial progress with its first commercialized product will help the stock price. But the company's performance will depend even more on future clinical and regulatory milestones, especially as it shows with Casgevy that it can manage the intricacies and complexities of marketing gene-editing medicines. Can the pipeline deliver? CRISPR Therapeutics has six candidates in clinical trials, which isn't bad at all for a mid-cap biotech company. One of its leading programs is CTX310, a potential therapy designed to help reduce low-density lipoprotein (LDL) cholesterol in patients with certain conditions. CTX310 is already producing encouraging clinical trial results. Additionally, it's an in vivo medicine, meaning it bypasses the need to harvest patients' cells to manufacture therapies; in vivo gene-editing treatments are easier to handle than their ex vivo counterparts. The company's path to creating life-changing returns hinges on its ability to deliver consistent clinical and regulatory wins over the next few years for CTX310 and other important candidates. If CRISPR Therapeutics can successfully launch several new products in the next five to seven years, its shares are likely to skyrocket. In the meantime, under this scenario, the company would succeed in making gene-editing medicines more mainstream. This would encourage third-party payers to get on board -- and healthcare institutions, and perhaps even governments, to help push for more ATCs, since there'd be a greater need to accommodate these treatments. Can CRISPR Therapeutics achieve this? In my view, the biotech stock is on the riskier side, but does carry significant upside potential. There's a (small) chance the gene-editing specialist will deliver life-changing returns in the next decade, but investors need to hedge their bets. It's best to start by initiating a small position in the stock, then progressively add more if CRISPR Therapeutics lands more wins. Should you invest $1,000 in CRISPR Therapeutics right now? Before you buy stock in CRISPR Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CRISPR Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Prosper Junior Bakiny has positions in Vertex Pharmaceuticals. The Motley Fool has positions in and recommends CRISPR Therapeutics and Vertex Pharmaceuticals. The Motley Fool has a disclosure policy. Here's How This Forgotten Healthcare Stock Could Generate Life-Changing Returns was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store